KMDA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Kamada · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 7.14 USD
1.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -9.6% below the Trend Line and sits at 30.1% of its 52-week range. The latest completed week returned 1.1%, after a -4.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 27/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: earnings are due in 10d.

Setup score 34 out of 100
Latest Close 7.14 USD 31 Jul 2026
1W Return 1.1% latest completed week
4W Return -4.8% short-term follow-through
12W Return -16.5% quarterly tape
Trend Breadth 48.1% 25 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.1% Latest completed week; four-week move -4.8%. Indicator stack 26/26 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 27/100 conviction; expected move 20.7%. News sentiment 57/100 47 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -9.6% below the Trend Line and sits at 30.1% of its 52-week range. The latest completed week returned 1.1%, after a -4.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1812-week average 0.47

12-week confirmation

Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -4.8% over four weeks, -16.5% over 12 weeks, and 1.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.1%
4W-4.8%
12W-16.5%
26W-11.6%
52W1.9%
Active trend streak0 weeks
Active weeks in one year25
Trend breadth48.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.33Latest activity-pressure read.
Pressure change0.2%Four-week change in activity pressure.
Leadership-12.00Latest relative-leadership reading.
RS change3.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 100% Model confidence 96%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength66/100Blend of value, momentum, and quality. Underlying universe rank 35; rank 1 is best.
Value69/100Relative valuation strength. Underlying universe rank 32; rank 1 is best.
Quality66/100Profitability and accounting quality. Underlying universe rank 35; rank 1 is best.
Momentum23/100Medium-term price momentum. Underlying universe rank 78; rank 1 is best.
Growth35/100Revenue and earnings growth. Underlying universe rank 66; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework45/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
20.0x
Price divided by trailing earnings.
Price / sales
2.2x
Market value relative to trailing revenue.
EV / EBITDA
10.1x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
9.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
41.2%
Gross profit retained from each unit of revenue.
Operating margin
12.7%
Operating profit retained from revenue.
Free-cash-flow margin
19.5%
Free cash flow generated from revenue.
Return on invested capital
8.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
8.6%
Latest one-year revenue growth.
EPS growth
26.8%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-36.3%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.5%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
3.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

KMDA shows mixed options pressure with a 27/100 conviction score, put-call volume ratio of n/a, expected move of 20.7%, and Sharemaestro trend signal inactive.

Conviction27/100
Expected move20.7%
Put/call volume
Pressure10
Speculation0
Volatility96
Trend agreement51
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment57/100

Weighted news tone is neutral across 47 relevant articles.

20 positive · 23 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move20.7%Nearest-chain priced movement where available.
52-week drawdown-21.3%Distance below the 52-week high.
13-week volatility4.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2614 weeks finished lower.
Best week+4.1%Week of 8 May.
Worst week-9.8%Week of 15 May.
Latest week+1.1%Week of 31 Jul.

Shape of recent returns

Strong gains1
Modest gains10
Flat weeks1
Modest losses11
Sharp losses3
Recent vol4.2%13-week weekly-return volatility.
Base vol3.7%52-week weekly-return volatility.
Up/down split22/29Count of positive and negative weeks in the 52-week window.
Average skew3.3% / -2.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape34/100

Trend, activity pressure, participation, and risk combine to a 34/100 tape read.

 Indicator analysis18/100

Latest 12-week confirmation: trend 3/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.18; No reversal markers Factors56/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 58; Small Cap Core rank 39 SVQF45/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 402.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options44/100

KMDA shows mixed options pressure with a 27/100 conviction score, put-call volume ratio of n/a, expected move of 20.7%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 20.7% Sentiment57/100

Weighted news tone is neutral across 47 relevant articles.

Price to book forward of Kamada Ltd. – NASDAQ:KMDA Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20267.14 USD1.1%7.90 USD6.24 USD-1.33-12.00235.7KOff
24 Jul 20267.06 USD0.1%7.89 USD6.23 USD-1.39-12.84169.9KOff
17 Jul 20267.05 USD-1.0%7.88 USD6.21 USD-1.35-14.76176.4KOff
10 Jul 20267.12 USD-5.1%7.88 USD6.20 USD-1.36-17.87127.1KOff
3 Jul 20267.50 USD3.3%7.87 USD6.18 USD-1.33-12.45128.7KOff
26 Jun 20267.26 USD-0.7%7.85 USD6.17 USD-1.37-14.97234.3KOff
19 Jun 20267.31 USD-1.7%7.83 USD6.15 USD-1.36-18.68152.4KOff
12 Jun 20267.44 USD3.8%7.80 USD6.14 USD-1.23-15.48172.1KOff
5 Jun 20267.17 USD-8.2%7.78 USD6.12 USD-1.08-16.98257.7KOff
29 May 20267.81 USD-0.3%7.76 USD6.11 USD-0.86-13.97204.1KOn
22 May 20267.83 USD1.6%7.72 USD6.09 USD-0.71-11.57303.1KOn
15 May 20267.71 USD-9.8%7.68 USD6.07 USD-0.61-12.11395.8KOn
8 May 20268.55 USD4.1%7.64 USD6.05 USD-0.44-3.16185.3KOn
1 May 20268.21 USD-0.8%7.58 USD6.02 USD-0.26-2.16203.1KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.